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KidneyBenefit of Apabetalone on Plasma Proteins
in Renal Disease
Sylwia Wasiak1,5, Laura M. Tsujikawa1,5, Christopher Halliday1, Stephanie C. Stotz1,
Dean Gilham1, Ravi Jahagirdar1, Kamyar Kalantar-Zadeh2, Richard Robson3,6,
Michael Sweeney4, Jan O. Johansson4, Norman C. Wong1 and Ewelina Kulikowski1
1Resverlogix Corp, Calgary, Alberta, Canada; 2University of California, Irvine School of Medicine, Orange, California, USA;
3Christchurch Clinical Studies Trust, Christchurch, New Zealand; and 4Resverlogix Inc., San Francisco, California, USAIntroduction: Apabetalone, a small molecule inhibitor, targets epigenetic readers termed BET proteins that
contribute to gene dysregulation in human disorders. Apabetalone has in vitro and in vivo anti-
inflammatory and antiatherosclerotic properties. In phase 2 clinical trials, this drug reduced the inci-
dence of major adverse cardiac events in patients with cardiovascular disease. Chronic kidney disease is
associated with a progressive loss of renal function and a high risk of cardiovascular disease. We studied
the impact of apabetalone on the plasma proteome in patients with impaired kidney function.
Methods: Subjects with stage 4 or 5 chronic kidney disease andmatched controls received a single dose of
apabetalone. Plasma was collected for pharmacokinetic analysis and for proteomics profiling using the
SOMAscan 1.3k platform. Proteomics data were analyzed with Ingenuity Pathway Analysis to identify
dysregulated pathways in diseased patients, which were targeted by apabetalone.
Results: At baseline, 169 plasma proteins (adjusted P value <0.05) were differentially enriched in renally
impaired patients versus control subjects, including cystatin C and b2 microglobulin, which correlate with
renal function. Bioinformatics analysis of the plasma proteome revealed a significant activation of 42
pathways that control immunity and inflammation, oxidative stress, endothelial dysfunction, vascular
calcification, and coagulation. At 12 hours postdose, apabetalone countered the activation of pathways
associated with renal disease and reduced the abundance of disease markers, including interleukin-6,
plasminogen activator inhibitor-1, and osteopontin.
Conclusion: These data demonstrated plasma proteome dysregulation in renally impaired patients and the
beneficial impact of apabetalone on pathways linked to chronic kidney disease and its cardiovascular
complications.
Kidney Int Rep (2018) 3, 711–721; https://doi.org/10.1016/j.ekir.2017.12.001
KEYWORDS: bromodomain; cardiovascular disease; chronic kidney disease; epigenetics; inflammation; proteomics
ª 2017 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C hronic kidney disease (CKD) afflicts approximately11% of the general worldwide population, and rep-
resents an important global health challenge.1 CKDevolves
over many years, with progressive loss of renal function,
which could eventually lead to renal replacement therapy
(dialysis) and kidney transplantation. Over the course
of the disease, there is a progressive increase in both
mortality and comorbidities, primarily due to the devel-
opment of cardiovascular disease (CVD).2 Consequently,
early therapeutic intervention is essential to slow CKDspondence: Dr. Ewelina Kulikowski, Resverlogix Corp, Suite
820 Richard Road SW, Calgary, Alberta, Canada T3E 6L1.
l: ewelina@resverlogix.com
e authors equally contributed to this work.
ipal investigator of the clinical trial.
ved 18 October 2017; revised 29 November 2017; accepted 4
ber 2017; published online 8 December 2017
International Reports (2018) 3, 711–721progression, prevent end-stage renal disease, and improve
the quality of life and longevity of patients.
CKD is characterized by heightened levels of
oxidative stress, advanced glycation end-products,
proinflammatory cytokines, and uremic toxins.3 Path-
ogenic signaling initiated by these factors induces
changes in epigenetic marks, including methylation
and acetylation on chromatin-associated proteins.4,5
BET proteins BRD2, BRD3, BRD4, and BRDT are
epigenetic readers that use small interaction modules
called bromodomains (BDs) to bind to acetylated lysi-
netagged histones and transcription factors associated
with transcriptionally active chromatin.6–8 Binding
leads to the recruitment of the transcriptional
machinery that drives gene expression.9–13 In
disease states, abnormal signaling often results in
overabundant or mislocalized acetylation marks, over-
expression of BET proteins, and increased BET protein711
Table 1. Demographic and clinical characteristics of patients
enrolled in the phase 1 pharmacokinetics study
Characteristics
Cohort 1 renal impaired
(n [ 8)
Cohort 2 controls
(n [ 8)
Age (yr) 55.9  16.5 52.6  16.5
Male sex 5 (63) 5 (63)
White race 8 (100) 8 (100)
Ethnicity
Non-Hispanic or Non-Latino 8 (100) 8 (100)
BMI (kg/m2) 28.1  5.1 25.5  3.0
Median clinical chemistry measures
Albumin (g/l) 36.0  4.1 39.8  3.1
Alkaline phosphatase (IU/l) 113.1  60.4 73.0  16.2
CKD-EPI (ml/min per 1.73 m2) 18.8  5.9 78.4  10.6
Serum creatinine (mmol/l) 305.3  104.9 87.9  10.3
Blood urea nitrogen (mmol/l) 21.9  10.5 6.1  1.9
Blood pressure
Systolic (mm Hg) 132.8  26.4 129.0  21.7
Diastolic (mm Hg) 67.4  14.8 71.5  12.7
Comorbidities
Hypertension 5 3
Hypo/hyperthyroidism 2 0
Diabetes 1 0
Hyperlipidemia 1 0
Peripheral vascular disease 1 0
Allergy 1 1
Autoimmune 1 1
Genetic disorder 1 0
Gastrointestinal 1 0
Values are number (%), mean  SD, or number.
BMI, body mass index; CKD-EPI, Chronic Kidney Disease-Epidemiology equation.
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changes to gene transcription patterns that control cell
fate, proliferation and activation in cancer, fibrosis,
autoimmunity, and inflammation.14–21 Recently, BET
proteins were shown to contribute to renal disorders,
including experimental polycystic kidney disease and
renal inflammatory disease.22–26 Importantly, in these
studies, small molecule inhibitors targeting the BDs of
BET proteins countered aberrant gene transcription,
which led to improved renal outcomes.22–24,26
Apabetalone (RVX-208) is a first-in-class orally
available BET inhibitor (BETi) developed to treat
CVD.27–32 In biochemical assays, apabetalone targeted
the second BD (BD2) of BET proteins with 20- to 30-fold
selectivity.33,34 In cells, BD2 binding by apabetalone
resulted in differential transcriptional effects compared
with a pan-BETi that targeted both BD1 and BD2 with
equal affinity.34,35 Apabetalone downregulated im-
mune, inflammatory, and proatherosclerotic genes in
ex vivotreated human blood cells and primary hepa-
tocytes, as well as in a mouse model of atheroscle-
rosis.30,36–38 Furthermore, apabetalone improved the
plasma lipid profiles of CVD patients and significantly
lowered the incidence of major adverse cardiac events
in the Study of Quantitative Serial Trends in Lipids
with Apolipoprotein A-I Stimulation (SUSTAIN) and
the ApoA-I Synthesis Stimulation and Intravascular
Ultrasound for Coronary Atheroma Regression Evalu-
ation (ASSURE) phase 2 trials.30,39 Although high-
potency pan-BETi are currently being tested for can-
cer indications,40 apabetalone was the first BETi to
enter clinical trials for the treatment of CVD. Deter-
mining the scope of the in vivo actions of apabetalone is
currently an area of active investigation.27–31
CKD is characterized by a strong immune and in-
flammatory component that contributes to accelerated
endothelial dysfunction, vascular inflammation,
atherosclerosis, and calcification.41,42 CKD patients often
succumb to cardiovascular complications because cur-
rent therapies fail to treat the key pathogenic mecha-
nisms underlying disease progression.43 To evaluate the
potential of apabetalone as a CKD therapeutic, we
examined the pharmacokinetics of apabetalone in a
phase 1, open-label, parallel group study of patientswith
an estimated glomerular rate (eGFR) of <30 ml/min per
1.73 m2. Using a novel aptamer-based proteomics
approach coupled to bioinformatics, we identified pro-
teins enriched in the plasma from patients with impaired
kidney function, relative to control subjects. Further-
more, we demonstrated that a single dose of apabetalone
downregulated plasma markers of endothelial dysfunc-
tion, atherosclerosis, vascular inflammation, calcifica-
tion, fibrosis, hemostasis, and chronic inflammation,
countering the pathogenic signaling in CKD patients.712These findings suggest that apabetalone treatment might
benefit CKD patients.
METHODS
Patient Selection
All procedures followed were in accordance with the
ethical standards of the responsible committee on
human experimentation (institutional and national) and
with the Helsinki Declaration of 1975, as revised in
2000. Informed consent was obtained from all patients
for being included in the study. The phase I apabet-
alone pharmacokinetic study consisted of 2 cohorts of 8
subjects each who received a single 100-mg oral dose of
apabetalone after a meal. Cohort 1 consisted of subjects
with stage 4 or 5 CKD who were not on dialysis, with
an eGFR of <30 ml/min per 1.73 m2 and a mean eGFR of
20 ml/min per 1.73 m2. Cohort 2 consisted of control
subjects matched to the renally impaired subjects in
age, weight, and sex, as well as an eGFR of $60 ml/min
per 1.73 m2, with mean eGFR of 78.5 ml/min per
1.73 m2. Additional characteristics of the cohorts are
provided in Table 1.
Apabetalone Pharmacokinetics and Safety
Blood samples for determination of plasma concentra-
tion of apabetalone were collected at the following timeKidney International Reports (2018) 3, 711–721
S Wasiak et al.: Apabetalone Counters Pathogenic Signaling in CKD Plasma TRANSLATIONAL RESEARCHpoints: baseline and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 34,
and 48 hours postdose. Total voided urine for deter-
mining urinary excretion of apabetalone was collected
over the following intervals: baseline (single-void), 0 to
4, 4 to 8, 8 to 12, 12 to 24, and 24 to 48 hours postdose.
Plasma and urine pharmacokinetic samples were ship-
ped to and processed by Intertek Pharmaceutical Ser-
vices (San Diego, California). Safety assessments
included monitoring of adverse events, vital signs,
clinical laboratory findings, 12-lead electrocardiograms,
and physical examination.SOMAscan Analysis
Patient plasma samples collected at baseline and at 6,
12, 24, 48 hours after the single apabetalone dose un-
derwent proteomic analysis using the SOMAscan 1.3k
platform (SomaLogic, Boulder, Colorado).44 SOMAscan
uses modified aptamers to simultaneously detect 1305
proteins. The assay can quantify proteins that span
over 8 logs in abundance (from femtomolar to micro-
molar), which allows direct analysis of plasma samples
without depletion of abundant proteins. The SOMAs-
can assay transforms protein concentrations into DNA
aptamer concentrations that are quantifiable on a DNA
microarray. Changes in relative fluorescent units,
which are directly proportional to the amount of target
protein in the initial sample, were expressed relative to
baseline.44Statistical Analysis
To assess the differential protein levels at baseline be-
tween cohort 1 and cohort 2, the Mann-Whitney test
was used when data were not normally distributed;
otherwise Student’s t-tests were used. The Benjamini-
Hochberg false discovery rate (FDR) multiple testing
correction was used to generate FDR-adjusted P values.
An adjusted P value < 0.05 was considered significant.
Shapiro-Wilk tests were used to determine data
distribution.
Changes in protein levels were compared from base-
line to 12 hours post-apabetalone dose in all patients.
For normally distributed protein parameters, paired
Student’s t-tests were used to examine the change in
protein levels, whereas the Wilcoxon signed-rank test
was applied for non-normally distributed parameters. A
P value < 0.05 was considered significant. Shapiro-
Wilk tests were used to determine data distribution.Pathway Analysis
QIAGEN’s Ingenuity Pathway Analysis software (IPA;
QIAGEN, Redwood City, California; www.qiagen.com/
ingenuity) was used to interpret the proteomics data.Kidney International Reports (2018) 3, 711–721RESULTS
Pharmacokinetics of Apabetalone in Control and
Stage 4 or 5 CKD Patients
In this study, we compared 8 subjects with eGFRs
ranging from 9 to 29 ml/min per 1.73 m2 (cohort 1, CKD
stage 4 or 5, and median creatinine clearance 18.8
ml/min per square meter) and 8 subjects with eGFR
ranging from 66 to 109 ml/min per 1.73 m2 (cohort 2,
age-, sex-, weight-matched, and median creatinine
clearance 78.4 ml/min per square meter). In addition to
stage 4 or 5 CKD, cohort 1 also displayed comorbidities
that commonly accompany renal disease, including
CVD, diabetes, and hypothyroidism (Table 1). Baseline
plasma samples were obtained from both cohorts to
assess clinical biochemistry parameters. Comparison of
apabetalone pharmacokinetics following a single dose
revealed that the maximum (peak) serum concentra-
tion, area under the curve, time to reach maximum
(peak) serum concentration (Tmax), and terminal half-
life were similar for both the renally impaired and
matched subjects (Supplementary Table S1). Minimal
amounts of apabetalone were excreted in the urine of
either cohort (Supplementary Table S2), which is
consistent with the elimination of apabetalone through
hepatic clearance. No significant adverse events
occurred during the study in the control or the CKD
cohorts (data not shown).Plasma Proteome Profiling in CKD Patients
To gain insight into the molecular mechanisms that
underlie CKD and its comorbidities, the proteomic
composition of plasma samples from late-stage CKD
(cohort 1) and control (cohort 2) subjects was assessed
at baseline with the SOMAscan 1.3k platform
(Figure 1a).44 Two hundred eighty-eight proteins were
differentially expressed between the 2 cohorts (differ-
ence >10%, P < 0.05, FDR <0.2) (Figure 1b and
Supplementary Table S3), forming a database for
functional pathway analysis. Upon correction for
multiple testing, 167 proteins remained significantly
upregulated, whereas 2 proteins were downregulated
in the CKD cohort (difference >10%, P < 0.005,
FDR <0.05) (Figure 1b and Supplementary Table S3,
column F).
CKD progression is accompanied by an overall in-
crease in the plasma concentration of low-molecular-
weight (LMW; <45 kDa) proteins due to a decline in
the filtration capacity of the kidneys.45,46 Analysis
showed that 173 of the 288 CKD cohort-enriched pro-
teins were LMW proteins. These LMW proteins
showed a greater fold enrichment in the CKD
cohort compared with proteins of >45 kDa (2.3  1.2
vs. 1.7  0.76, respectively; P ¼ 0.000024; Student’s713
Cohort 1
Renal Impaired
(n = 8)
Cohort 2
Age-, Weight-, Gender-
Matched
eGFR>60 ml/min per 1.73 m2eGFR<30 ml/min per 1.73 m2
(n = 8)
Proteome Analysis
SOMAscan Assay
Statistical Analysis
288 differentially 
expressed proteins
enrichment >10%
P < 0.05
Ingenuity Pathway Analysis
169 differentially 
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P < 0.005
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Figure 1. SOMAscan analysis of the plasma proteome. Study design flowchart (a). Proteins differentially expressed in the CKD cohort are
plotted according to their fold enrichment (b). The degree of significance is color coded (see legend). Note that p values tend to be highly
significant for highly enriched proteins. Fold enrichment as a function of protein molecular weight (c). Note that the majority of enriched
proteins have a molecular weight of <45 kDa. Protein enrichment also tends to be greater for proteins with molecular weight <45 kDa.
Table 2. Gene ontology term molecular function analysis of CKD-
enriched proteins: top 21 terms (z-score >2.0; P < 0.0001)
GO term Molecular function P value
GO:0005102 Receptor binding 4.0  1045
GO:0005125 Cytokine activity 2.7  1023
GO:0005126 Cytokine receptor binding 1.7  1022
GO:0005515 Protein binding 8.5  1019
GO:0004872 Receptor activity 8.1  1013
GO:0060089 Molecular transducer activity 8.1  1013
GO:0019955 Cytokine binding 8.3  1013
GO:0008083 Growth factor activity 1.2  1012
GO:0008009 Chemokine activity 5.4  1011
GO:0004871 Signal transducer activity 1.9  1010
GO:0005035 Death receptor activity 2.8  1010
GO:0005031 Tumor necrosis factor-activated receptor activity 2.8  1010
GO:0019199 Transmembrane receptor protein kinase activity 3.2  1010
GO:0042379 Chemokine receptor binding 8.4  1010
GO:0001664 G-protein coupled receptor binding 1.1  108
GO:0005488 Binding 3.0  108
GO:0038023 Signaling receptor activity 5.1  108
GO:0005539 Glycosaminoglycan binding 5.9  108
GO:0004896 Cytokine receptor activity 2.4  107
GO:0019838 Growth factor binding 3.1  107
GO:0048020 CCR chemokine receptor binding 6.0  107
GO, gene ontology.
TRANSLATIONAL RESEARCH S Wasiak et al.: Apabetalone Counters Pathogenic Signaling in CKD Plasmat-test) (Figure 1c). Many of the enriched LMW proteins
are well-established biomarkers that correlate
with kidney function,47 including cystatin C
(3.1-fold), b-2-microglobulin (5-fold), neutrophil gelat-
inaseassociated lipocalin (4.6-fold), liver fatty acid-
binding protein (2.7-fold), and fibroblast growth
factor 23 (1.8-fold) (Supplementary Table S3 and ref-
erences therein). Numerous uremic toxins, as classified
by the European Toxin Work Group,45 were also
upregulated in the CKD cohort (Supplementary
Table S4). Other enriched proteins included cytokines
and their soluble receptors, adhesion molecules, met-
alloproteases, and complement and coagulation pro-
teins, as well as factors involved in calcification,
metabolism, and oxidative stress (Supplementary
Table S3).
Gene ontology analysis48 of theCKDcohortassociated
proteins (FDR<0.2) showed significant enrichment of 53
terms in the molecular function category (Supplementary
Table S5). The top 21 enriched terms (Table 2) were
related to ligand-receptor signaling, with 9 linked to
cytokine and chemokine pathways. IPA,49 with its
manually curated database from peer-reviewed literature,
further predicted not only the impact of disease
on cellular functions (P values), but also the direction
of change by calculating the activation z-score
(Supplementary Table S6). Analysis showed that 234
“disease or function” annotations were increased in the
CKD cohort (z score >2), whereas 6 annotations were
decreased (z score <2). In particular, top pathways
714(Table 3) which referred to immune and inflammatory
cell migration, proliferation, differentiation, activation,
and viability, were all upregulated in plasma from
the CKD cohort compared with the control cohort. The
IPA analysis also predicted a marked upregulation of 42
canonical pathways (z score>2) and a downregulation ofKidney International Reports (2018) 3, 711–721
Table 3. Ingenuity Pathway Analysis disease or functions analysis
of CKD-enriched proteins: top 21 terms (z score >2.0; P < 0.0001)
IPA: diseases or functions annotation Z score P value
Cell movement 6.2 7.9  1074
Migration of cells 6.4 1.1  1071
Leukocyte migration 5.7 3.1  1063
Cell movement of leukocytes 5.3 1.5  1058
Proliferation of cells 4.5 4.8  1056
Cell movement of myeloid cells 5.0 5.6  1052
Quantity of cells 2.3 2.3  1051
Activation of cells 5.2 3.7  1050
Cell movement of phagocytes 5.4 7.4  1049
Activation of blood cells 4.4 7.0  1047
Inflammatory response 4.1 9.4  1047
Activation of leukocytes 4.7 1.2  1044
Quantity of blood cells 2.9 5.0  1044
Cell movement of granulocytes 4.5 2.9  1042
Chemotaxis 5.9 5.2  1041
Quantity of leukocytes 2.8 1.4  1040
Homing of cells 5.8 2.3  1040
Recruitment of cells 3.8 3.6  1040
Differentiation of cells 4.6 4.6  1039
Growth of tumor 3.7 1.7  1038
Cell movement of mononuclear leukocytes 5.1 4.5  1038
IPA, Ingenuity Pathway Analysis.
Table 4. Ingenuity Pathway Analysis canonical pathway analysis of
proteins enriched in the CKD cohort and the impact of apabetalone
in the CKD cohort at 12 hours postdose versus baseline
Ingenuity Pathway Analysis
CKD vs. control:
baseline CKD: apabetalone
z score P value z score P value
Dendritic cell maturation 3.46a <0.0001 4.12b <0.0001
IL-6 signaling 3.21a <0.0001 3.46b <0.0001
Th1 pathway 3.16a <0.0001 3.32b <0.0001
Colorectal cancer metastasis signaling 3.13a <0.0001 3.50b <0.0001
NF-kB signaling 3.05a <0.0001 3.46b <0.0001
Acute phase response signaling 2.89a <0.0001 3.46b <0.0001
HMGB1 signaling 2.84a <0.0001 3.50b <0.0001
IL-17A signaling in airway cells 2.83a <0.0001 2.33b <0.0001
Type I diabetes mellitus signaling 2.83a <0.0001 2.65b <0.0001
Role of NFAT in cardiac hypertrophy 2.83a 0.004 <0.0001
Death receptor signaling 2.83a <0.0001 2.12b <0.0001
p38 MAPK signaling 2.65a 0.0008 3.32b <0.0001
STAT3 Pathway 2.53a <0.0001 1.63 0.0002
Production of nitric oxide and reactive
oxygen species in macrophages
2.50a <0.0001 3.16b 0.0001
VEGF family ligand-receptor interactions 2.45a 0.001 3.16b <0.0001
VEGF signaling 2.45a 0.003 2.33b <0.0001
Nitric oxide signaling in the
cardiovascular system
2.45a 0.006 3.00b <0.0001
Induction of apoptosis by HIV1 2.45a 0.0001 1.63 <0.0001
PAK signaling 2.45a 0.002 2.65b 0.0002
CNTF signaling 2.45a 0.0002 2.00b 0.006
Oncostatin M signaling 2.45a <0.0001 0.007
Pancreatic adenocarcinoma signaling 2.33a <0.0001 2.53b <0.0001
ILK signaling 2.33a 0.001 2.89b <0.0001
Renin-angiotensin signaling 2.33a <0.0001 2.83b 0.0001
Cardiac hypertrophy signaling 2.33a 0.004 3.16b 0.0006
Role of pattern recognition receptors in
recognition of bacteria and viruses
2.24a 0.0004 2.45b <0.0001
IL-22 signaling 2.24a <0.0001 1.63 <0.0001
Tec kinase signaling 2.24a 0.02 3.16b <0.0001
Role of NANOG in mammalian embryonic
stem cell pluripotency
2.24a 0.001 2.45b <0.0001
Coagulation system 2.24a <0.0001 0.45 <0.0001
Type 2 diabetes mellitus signaling 2.24a 0.04 3.00b <0.0001
NGF signaling 2.24a 0.02 2.65b 0.0006
Melanocyte development and
pigmentation signaling
2.24a 0.008 2.24b 0.005
Corticotropin releasing hormone signaling 2.24a 0.0009 2.00b 0.01
Notch signaling 2.24a 0.0001 0.07
BMP signaling pathway 2.12a <0.0001 2.45b 0.0003
IL-8 signaling 2.11a <0.0001 3.74b <0.0001
PEDF signaling 2.00a 0.004 2.53b <0.0001
GM-CSF signaling 2.00a 0.02 3.00b <0.0001
Role of PI3K/AKT signaling in the
pathogenesis of influenza
2.00a 0.02 2.83b <0.0001
Role of IL-17F in allergic inflammatory
airway diseases
2.00a <0.0001 0.0002
Ephrin B signaling 2.00a 0.003 0.6
PPAR signaling 2.12b <0.0001 2.24a 0.005
Antioxidant action of vitamin C 2.24b 0.01 2.45a 0.0003
BMP, bone morphogenetic protein; CNTF, ciliary neurotrophic factor; ILK, integrin-linked
protein kinase; GM-CSF, granulocyte-macrophage colony-stimulating factor; HMGB1,
high mobility group box-1; IL, interleukin; MAPK, mitogen-activated protein kinase;
NANOG, nanog homeobox; NFAT, nuclear factor of activated T-cells; NF-kB, nuclear
factor-kB; NGF, nerve growth factor; PAK, p-21-activated kinase; PEDF, pigment
epithelium-derived factor; PPAR, peroxisome proliferator–activated receptor; VEGF,
vascular endothelial growth factor.
aPredicated activation is indicated by a z score >2.0.
bPredicated repression is indicated by a z score <2.
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and inflammatory responses, endothelial dysfunction,
coagulation, renin-angiotensin system, calcification, and
oxidative stress (Table 4). Thus, our bioinformatics
analysis highlighted many of the underlying dysfunc-
tional pathways that contribute to CKD and its
comorbidities.
Apabetalone Downregulates Markers and Path-
ways Upregulated in Plasma From Renally
Impaired Cohort
To enable assessment of the CKD cohort’s response to
apabetalone, target engagement was evaluated at mul-
tiple time points postdose. At 12 hours, the known
BETi target engagement marker lymphocyte activation
gene 3 (LAG3)18,23 was maximally downregulated
(Supplementary Figure S1). Recovery of LAG3 plasma
expression was observed following drug clearance
(Supplementary Figure S1). Therefore, the impact of
apabetalone on plasma protein levels in the CKD cohort
was analyzed 12 hours postdose (Table 5).
Numerous plasma proteins with physiological func-
tions relevant for CKD and CVD were downregulated by
apabetalone in the CKD cohort. Circulating proathero-
genic, inflammatory cytokines interleukin (IL)-6, IL-1,
IL-17, IL-12, and IL-23, as well as the IL-15 receptor
subunit a, decreased in abundance with apabetalone
treatment (10%29%) (Table 5). Apabetalone reduced
levels of metalloproteases (MMP-3, MMP-10) and
extracellular matrix proteins (fibronectin, osteopontin)Kidney International Reports (2018) 3, 711–721 715
Table 5. Effect of apabetalone on CKD and cardiovascular disease protein biomarkers in plasma from CKD and control patients
Protein Gene
CKD vs. control: baseline CKD (n [ 8): apabetalone Control (n [ 8): apabetalone
Baseline Ratio P valuea % Change from baselineb P valuec % Change from baselineb P valuec
Inflammation
IL-6 IL6 1.3 0.1 29.0 0.05 42.3 0.25
IL-17A IL17A 1.2 0.4 13.3 0.02 7.8 1.00
IL-15 receptor subunit a IL15RA 2.5 0.0002 12.0 0.02 8.5 0.84
IL-12 IL12A IL12B 1.0 0.3 11.5 0.04 3.4 1.00
IL-23 IL12B IL23A 3.3 0.003 11.3 0.01 3.4 0.64
IL-1 a IL1A 1.4 0.1 10.8 0.01 1.3 0.55
Extracellular matrix remodelling
Fibronectin FN1 1.0 0.9 24.7 0.02 3.6 0.55
Fibronectin fragment 3 FN1 1.1 0.5 18.0 0.04 3.5 0.55
Stromelysin-1 MMP3 3.0 0.002 15.4 0.02 7.4 0.84
Stromelysin-2 MMP10 2.4 0.0002 10.9 0.02 1.8 0.55
Fibronectin fragment 4 FN1 1.3 0.05 10.6 0.04 14.6 0.55
Vascular calcification
Osteopontin SPP1 3.6 0.0002 17.9 0.01 15.9 0.04
Thrombosis, fibrinolysis, and platelet activation
Plasminogen activator inhibitor 1 SERPINE1 0.9 1 41.6 0.04 11.0 0.84
Tissue-type plasminogen activator PLAT 0.7 0.6 27.8 0.01 14.3 0.11
P-selectin SELP 1.0 0.9 22.5 0.04 8.0 0.74
Urokinase-type plasminogen activator PLAU 1.1 1 17.5 0.01 11.7 0.02
Complement activation
Complement C3b C3 0.4 0.07 19.0 0.04 8.7 0.95
C5a anaphylatoxin C5 1.8 0.01 12.1 0.04 22.4 0.01
Complement C3d fragment C3 1.0 0.4 10.5 0.04 9.0 0.02
IL, interleukin.
aP value comparing baseline between cohorts calculated using Mann-Whitney test.
bResults expressed as median percent change from baseline.
cP value comparing change vs. baseline calculated using the Wilcoxon signed-rank test.
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regulated, including plasminogen activator inhibitor-1,
tissue-type plasminogen activator, and urokinase-like
plasminogen activator (42%, 28% and 18%, respec-
tively), as well as a marker of platelet activation and
vascular inflammation, P-selectin (23%). Furthermore,
apabetalone decreased the abundance of activated frag-
ments of complement proteins, including anaphylatoxin
C5a (12%) (Table 5). In contrast, apabetalone had limited
effects on disease biomarkers in the control cohort
(Table 5).
To gain insight into the functional effects of apa-
betalone, the impact of apabetalone on the IPA ca-
nonical pathways upregulated in plasma from the
CKD cohort was assessed (Table 4). Remarkably,
apabetalone reversed the activation of 33 of 42
pathways in the CKD cohort, with the greatest impact
on pathways that were most upregulated in the CKD
patients (Table 4). These canonical pathways regulate
inflammation through cytokine signaling, acute phase
response, T-cell, and dendritic cell responses.
Further, apabetalone downregulated other pathways
relevant to CKD pathophysiology: vascular calcifica-
tion (bone morphogenetic protein signaling), fibrosis
(integrin-linked protein kinase signaling), apoptosis716(death cell receptor signaling), angiogenesis (vascular
endothelial growth factor and pigment epithelium-
derived factor signaling), nitric oxide, and reactive
oxygen species signaling. Moreover, intracellular
signaling pathways converging on the transcription
factor nuclear factor-kB (NF-kB) were also down-
regulated by apabetalone, whereas the peroxisome
proliferator–activated receptor pathway was upre-
gulated, countering pathogenic signaling in CKD.50,51
Finally, pathways that contribute to comorbidities,
such as hypertension, diabetes, and cardiac hyper-
trophy, were also downregulated by apabetalone
(Table 4). Overall, apabetalone simultaneously
modulated multiple pathways that contribute to CKD
pathology and associated vascular complications.DISCUSSION
Changes in plasma protein composition are a central
feature of CKD pathophysiology and its associated
comorbidities. Until recently, however, attempts to
study the plasma proteome have been hampered by the
complexity of the plasma protein composition and
inherent limitations of mass spectrometry.52–54
SOMAscan is a powerful protein discovery tool thatKidney International Reports (2018) 3, 711–721
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of various cellular functions.44 Here, a total of 169
proteins (adjusted P < 0.05) were identified as differ-
entially expressed in plasma from control and renally
impaired cohorts. Approximately 60% were LMW
proteins (<45 kDa), consistent with the impairment of
kidney filtration in late stage CKD.45,46 The plasma
proteome presented here shows little overlap with
previously published mass spectrometry driven studies
(Supplementary Table S3, column J).52–54 In contrast,
our data largely corroborates the results of a previous
SOMAscan study,44 in which a smaller panel (614
aptamers) was used to assess stages 3 to 5 CKD patient
plasma composition. Forty-five of the 60 markers
identified by Gold et al.,44 were also detected in this
study (Supplementary Table S3, column J). Differences
may be due to cohort size and composition. Many of
the enriched proteins are well established CKD bio-
markers that correlate with kidney function and CKD
or CVD outcomes (Supplementary Table S3, columns H
and I). These proteins play a role in inflammation,
vascular calcification, thrombosis, cell adhesion,
extracellular matrix remodeling, oxidative stress, and
metabolism. Interestingly, several of the enriched
proteins we identified have not been previously linked
to CKD or CVD. Establishing the functional relevance of
these novel CKD cohort-enriched proteins and deter-
mining their prognostic value presents exciting ave-
nues for future studies.
Analysis of plasma from renally impaired patients
revealed that a single dose of apabetalone rapidly
downregulated multiple CKD and CVD protein markers
(Table 5), as well as associated molecular pathways
(Table 4). In contrast, in the control cohort, apabetalone
had no significant effect on pathway activation or
repression (as determined by the IPA z-score; data not
shown), or on the abundance of most circulating dis-
ease markers (Table 5). This differential sensitivity to a
BET protein inhibitor highlights the dysregulation of
BET protein-dependent pathways in human CKD,
which is consistent with published data from cell and
animal models.21,23,26
Inflammation contributes to the onset and progres-
sion of renal disease.41 Indeed, 40% of the 288 proteins
upregulated in the CKD cohort are directly or indi-
rectly linked to inflammation (Supplementary
Table S3). The most prevalent among these are cyto-
kines and chemokines known to be dysregulated in
CKD and its comorbodities.55 In plasma from the CKD
cohort, there was an increase in circulating cytokines
(Supplementary Table S3), and pathways controlled by
IL-6, IL-17, oncostatin M, IL-22, IL-8, and granulocyte-
macrophage, colony-stimulating factor were predicted
to be activated (Table 4). Significantly, a single dose ofKidney International Reports (2018) 3, 711–721apabetalone reduced the plasma protein levels of
multiple cytokines and chemokines, including IL-6,
IL-12, IL-17, and IL-23 (Table 5). In addition, apabet-
alone was predicted to counter the CKD
cohortassociated upregulation of cytokine pathways,
including IL-6, IL-8, and IL-17 (Table 4). Essential
components of the innate and adaptive immune sys-
tem56,57 were among the top upregulated pathways in
the CKD cohort, including the dendritic cell matura-
tion and Th1 signaling pathways (Table 4, and
Supplementary Figures S2 and S3). Extensive cross-talk
occurred between these 2 pathways, with activated
dendritic cells stimulating inflammatory Th1 lympho-
cyte responses, which, in turn, promoted dendritic cell
maturation.58 Apabetalone had a significant impact on
both pathways (z scores: 4.2 and 3.3, respectively)
(Table 4, and Supplementary Figures S2 and S3), which
was consistent with published data.30,38
Inflammatory cytokines such as IL-6 induce the
acute phase response (APR) protein expression and
secretion by the liver.59 Multiple APR proteins were
upregulated in plasma from the CKD cohort potentially
due to increased IL-6 signaling (as predicted by IPA)
(Supplementary Table S3 and Supplementary
Figures S4 and S5). APR signaling pathway was
ranked the sixth most activated pathway in CKD
plasma (Table 4). APR proteins are markers of disease
progression and become highly enriched in the plasma
of stage 3 and 4 CKD patients.53,54 Interestingly, this
enrichment is greater in plasma of patients with CKD
than in the plasma of CVD patients,53 which indicates
that inflammation is exacerbated in patients with
advanced kidney failure.41 Of note, the APR
pathway was robustly downregulated by apabetalone
(z score: 3.46) (Table 4 and Supplementary Figure S5),
in line with previously published data.30,37,38
Consistent with the susceptibility of CKD patients
to thrombosis and bleeding,60 the coagulation system
pathway was upregulated in plasma from the CKD
cohort (Table 4). Several circulating hemostatic factors
were predictive of CVD events.61,62 Apabetalone
significantly decreased markers of the fibrinolysis
pathway (including plasminogen activator inhibitor-
1, urokinase-like plasminogen activator, and tissue-
type plasminogen activator) (Table 5), which are
associated with disturbances in hemostasis63 and
atherosclerosis64 in CKD patients. Inflammation and
coagulation can activate the complement cascade,
propagating and amplifying proinflammatory
signaling and damage.65 In agreement with previous
studies,37 apabetalone reduced the plasma concentra-
tion of activated C3 fragments and of the anaphyla-
toxin C5a, a marker that has been correlated with CVD
outcomes.66–68 To date, no adverse events related to717
TRANSLATIONAL RESEARCH S Wasiak et al.: Apabetalone Counters Pathogenic Signaling in CKD Plasmacoagulation nor complement system dysregulation
have been observed in clinical trials with apabet-
alone37 (and unpublished data).
Increased acetylation of gene promoters and tran-
scription factors such as STAT3 and NF-kB have been
detected in cultured renal cells and animal models of
inflammatory renal disease.23,69–71 These aberrant
acetylated lysine residues become the target of BET
proteins (e.g., BRD4) that then drive transcription of
inflammatory genes.23,71 Apabetalone downregulated
the abundance of multiple NF-kB target proteins in
plasma from the CKD cohort, including IL-6, IL-1a,
IL-12, IL-23, MMP-3, and plasminogen activator
inhibitor-1 (Table 5), and decreased the predicted
activation of the NF-kB signaling pathway
(z-score: 3.5) (Table 4 and Supplementary Figure S6).
These data corroborate previously reported inhibition
of NF-kBdependent pathways by BETi.16,23
Current therapies fail to counter progressive sys-
temic inflammation, endothelial dysfunction, vascular
calcification, fibrosis, and atherosclerosis in patients
with CKD.43 The plasma proteome study reported here
demonstrated that apabetalone might oppose many of
these pathogenic pathways in patients with CKD (and
its accompanying comorbidities) by rapidly down-
regulating plasma markers associated with these dys-
functions. Considering its favorable pharmacokinetic
properties in CKD patients and a well-established safety
profile,29,32 apabetalone is a potential therapeutic agent
capable of modulating molecular pathways associated
with risk factors that drive CKD progression and its
cardiovascular complications.
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by all authors.718SUPPLEMENTARY MATERIAL
Table S1. Pharmacokinetic assessment of the renal
impaired cohort 1 and matched control cohort 2
following a single apabetalone dose (100 mg).
Table S2. Urine output measured as the fractional
excretion (Fe%) of apabetalone for the renal impaired
cohort 1 and matched control cohort 2 following a single
apabetalone dose (100 mg).
Table S3. Complete annotated list of 288 proteins
enriched in CKD (P < 0.05, Mann-Whitney test). Base-
line comparison of cohort 1 versus cohort 2 (enrichment:
red indicates upregulation, blue indicates down-
regulation), and its statistical significance are shown in
columns D, E, and F. References supporting links to
renal, cardiovascular or inflammatory diseases and dia-
betes are listed columns H and I). Plasma proteomic
studies that identified protein enrichment in CKD pa-
tients are cited (column J).
Table S4. Uremic toxins enriched in the plasma from CKD
cohort relative to the control cohort.
Table S5. Gene ontology term molecular function analysis
of proteins enriched in CKD plasma: complete list of 53.
Table S6. Ingenuity Pathway Analysis disease or functions
analysis of proteins enriched in CKD plasma: complete list.
Figure S1. Target engagement time course. Apabetalone
(blue circles and line) and LAG3 (orange diamonds
and line) serum concentrations measured at discrete
time intervals following a single apabetalone dose.
Representative data from a single patient.
Figure S2. Ingenuity Pathway Analysis canonical pathway
analysis: dendritic cell maturation. Predicted signaling in
CKD plasma (A). Predicted changes in response to
apabetalone 12 hourpost single dose (B). Yellow and
turquoise: measured upregulation or downregulation in
protein abundance. Orange and blue: predicted
upregulation or downregulation. Pink outline: proteome
data.
Figure S3. Ingenuity Pathway Analysis canonical pathway
analysis: Th1 signaling. Predicted signaling in CKD
plasma (A). Predicted changes in response to single
apabetalone 12 hour postdose (B). Yellow and turquoise:
measured upregulation or downregulation in protein
abundance. Orange and blue: predicted upregulation or
downregulation. Pink outline: proteome data.
Figure S4. Ingenuity Pathway Analysis canonical pathway
analysis: interleukin-6 signaling. Predicted signaling in
CKD plasma (A). Predicted changes in response to single
apabetalone 12 hour postdose (B). Yellow and turquoise:
measured upregulation or downregulation in protein
abundance. Orange and blue: predicted upregulation or
downregulation. Pink outline: proteome data.
Figure S5. Ingenuity Pathway Analysis canonical pathway
analysis: acute phase response signaling. Predicted
signaling in CKD plasma (A). Predicted changes inKidney International Reports (2018) 3, 711–721
S Wasiak et al.: Apabetalone Counters Pathogenic Signaling in CKD Plasma TRANSLATIONAL RESEARCHresponse to single apabetalone 12 hour postdose (B).
Yellow and turquoise: measured upregulation or
downregulation in protein abundance. Orange and blue:
predicted upregulation or downregulation. Pink outline:
proteome data.
Figure S6. Ingenuity Pathway Analysis canonical pathway
analysis: nuclear factor-kb signaling. Predicted signaling
in CKD plasma (A). Predicted changes in response to
single apabetalone 12 hour postdose (B). Yellow and
turquoise: measured upregulation or downregulation in
protein abundance. Orange and blue: predicted
upregulation or downregulation. Pink outline: proteome
data.
Supplementary material is linked to the online version of
the paper at www.kireports.org.
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